



The Joint International Conference of the Israeli Society of Oral Medicine
Multinational Association of Supportive Care in Cancer
International Society of Oral Oncology
Israeli Society of Clinical Oncology and Radiotherapy

Multidisciplinary Approach to Oral Supportive Care in Cancer

1-2 November, 2018

Dan Panorama Hotel, Tel Aviv, Israel



Dear Colleagues,

Israeli Society of Oral Medicine is proud to invite the entire dental community to a one of a kind International conference that will discuss the multidisciplinary approach to oral complications in oncology patients. The overall cancer community is growing and at the same time, there is a dramatic increase in the development of new treatment modalities. As a result, there has been a dramatic increase in the incidence of oral complications and helping this special community of patients remains a challenge.

Dentists play a central role in managing oncology patients, in both prevention and active treatment. In addition, oncology treatment impacts greatly on the conventional dental treatment plan and it is prudent to understand the facts in order to provide the most optimum care and avoid untoward complications.

The goal of this conference is to review the relevant issues and to introduce both the conventional and most updated treatment recommendations. For this purpose, the conference is in collaboration with several local and international societies with knowledge in this field, together with the participation of world-renowned experts from Israel, the United States and Canada as they have graciously agreed to share their expertise on this subject with the entire Israel dental community.

Additional information, registration forms and instructions for abstract submissions can be found [here](#). We are wishing for a successful and productive conference.



Dr. Noam Yarom
Chairman of the
Scientific Committee



Dr. Eli Michaeli
Chairman of the
Organizing Committee



Dr. Galit Almozino
President, Israeli Society
of Oral Medicine



Stephen T. Sonis

Dana-Farber Cancer Institute. Boston

Dr Sonis is a senior academic and research scientist. Dr. Sonis is a Professor of Oral Medicine at the Harvard School of Dental Medicine, Senior Surgeon at Brigham and Women's Hospital and a Distinguished Physician at the Dana-Farber Cancer Institute.

After receiving his DMD from Tufts, Dr. Sonis completed a combined doctorate and residency at Harvard and its affiliated hospitals and was a Knox Fellow at Oxford (UK) where he studied tumor immunology.

Dr Sonis's studies on the molecular and cellular pathogenesis of cancer regimen-related tissue damage have established the basis of a mechanistic paradigm for epithelial injury, and have provided treatment targets for biological and pharmaceutical development. Recognizing that genetics plays a role in patient risk for mucositis and other toxicities, Dr. Sonis and his collaborators have developed and used innovative analytics to identify specific canonical pathways that are critical in toxicity development and have applied their findings to form the basis for models of gene-based risk prediction. His broad experience in clinical trial design and innovative end point quality management have been recognized as key components in the success of interventional trials in cancer supportive care.

In addition to his academic appointments, Dr. Sonis is the Chief Scientific Officer of Biomodels, LLC; Co-Founder and Chief Scientific Advisor of Inform Genomics; Past president of TRIAD Burden of Illness Studies, a not-for-profit company focusing on the adverse health and economic outcomes of cancer toxicities; co-Founder and Chief Scientific Officer of Primary Endpoint Solutions, LLC, and a special government employee of the U.S. FDA. He also serves as an Entrepreneur-in-Residence at the Harvard Innovation Labs of Harvard University.

Dr. Sonis has published extensively on the clinical, biological, and health economic aspects of cancer and complications associated with its treatment. He is the author of more than 275 original publications, reviews, and chapters, 10 books and 5 patents.

INTERNATIONAL SPEAKERS



Sharon Elad

University of Rochester. Rochester. NY

Dr. Elad is a Professor and Chair of the Division of Oral Medicine, at the Eastman Institute for Oral Health (EIOH), at the University of Rochester. In addition, she is the Clinical Chief for Hospital General Dentistry at Strong Memorial Hospital, at the University of Rochester Medical Center.

Dr. Elad is currently the Chair of the MASCC/ISOO Mucositis Study Group (MSG). Dr. Elad is also the section head for GVHD and for Viral Infections in the MASCC/ISOO Oral Care Study Group (OCSG). During the years of service in the MSG and OCSG leadership as well as in the ISOO Board she took a lead role in the development and publication of several guidelines and position papers.

Dr. Elad published extensively in professional journals, co-authored multiple book chapters and is an editorial board member in several medical journals. She is most proud of the Honorary Diplomate Award she received from the American Board of Oral Medicine.



Deborah P Saunders

North East Cancer Center, Sudbury, Ontario

Dr Saunders graduated from the University of Manitoba, Faculty of Dentistry in 1999 and resumes a full time practice as the Medical Director of the Department of Dental Oncology, Program Lead for Clinical Tobacco Intervention and the Oral Maxillofacial Rehabilitation Program at the Health Sciences

North, Northeast Regional Cancer Centre and is Assistant Professor at the Northern Ontario School of Medicine. She is the incoming President and Chair of the Oral Care Study Group of the International Society of Oral Oncology. Her areas of research include interest in MRONJ, ORN, oral mucositis, clinical tobacco intervention and genetic phenotyping in the oncology setting. She is an avid promoter of patient education and knowledge translation between research and clinical care.



Cherry L. Estilo

Memorial Sloan Kettering Cancer Center. NYC, NY

Cherry L. Estilo, DMD is an Attending and Clinical Member in the Dental Service, Department of Surgery at Memorial Sloan Kettering Cancer Center (MSKCC) and an Associate Professor of Surgery (Dentistry, Oral and Maxillofacial Surgery) at The Weill Cornell Medical College, New York, NY USA. Since March 2006, she has served as the Director of the

Dental Oncology Fellowship program at MSKCC and liaison for the rotation program with general practice dental residents of Weill Medical College of Cornell University, New York Presbyterian Hospital.

At MSKCC, Dr. Estilo is involved with patient care, education and research. Her clinical research interests focus on the dental and oral effects of cancer therapies. She has published in peer-reviewed journals in topics including osteoradionecrosis and other sequelae and complications of head and neck radiation therapy, the effects of pediatric cancer treatment on dental development and medication-related osteonecrosis of the jaw. She participates in various collaborative projects within MSKCC and with colleagues from institutions both nationally and internationally. She is an active member of the MASCC/ISOO, American Academy of Oral Medicine and EORTC Quality of Life group.



Cyril Meyerowitz

University of Rochester. Rochester. NY USA
DDS, MS, Professor and Director Emeritus, Eastman Institute
for Oral Health, University of Rochester.

Dr. Cyril Meyerowitz is Professor and Director Emeritus of the Eastman Institute for Oral Health at the University of Rochester and Director of the Northeast Region of the National Institute for Health (NIH) funded, National Dental Practice-Based Research Network.

He received his dental degree from the University of Witwatersrand, School Of Dentistry (South Africa) in 1973, and an MS degree in Dental Research from the University of Rochester in 1979. He completed residency training in general dentistry and a clinical and research fellowship at Eastman Dental Center/University of Rochester. Throughout his career he has been involved in dental education and research, serving nationally on the Commission on Dental Accreditation, the Commission for Change and Innovation of the American Dental Education Association and as chair of the Council of Dental Education and Licensure of the American Dental Association.

Dr Meyerowitz' research has been translational in nature focusing on salivary dysfunction and its relationship to dental caries, the relationship of systemic diseases to oral health, and, more recently, practice-based research. He has received NIH and commercial funding for this work. He has an active interest in dental educational research and in training clinical researchers, and he has been the principal investigator on NIH funded clinical research training grant awards.

Dr Meyerowitz has published extensively in peer reviewed journals and contributed numerous chapters to text books. He has presented to health care, educational and governmental bodies at the local, state, national and international level, and has been honored by professional and academic organizations.

SCIENTIFIC PROGRAM

Thursday, November 1st

08:00-08:30 Registration

08:30-09:00 Opening remarks

1st Session

09:00-09:30 **Stephen T Sonis** DMD, DMSc
The role of genomics and precision medicine in regimen-related toxicities

09:30-10:00 **Deborah P Saunders** DMD, BSc
Translating knowledge to patient care: pharmacologic and non-pharmacologic management of oral complications in cancer therapy

10:00-10:30 **Sharon Elad** DMD, MSc
MASCC/ISOO clinical practice guidelines for the management of mucositis – 2018 update

10:30-11:00 Coffee break and poster exhibition

2nd Session - Immunotherapy

sponsored by  **MSD** and  **Bristol-Myers Squibb**

11:00-11:20 **Gal Markel** MD, PhD
Introduction to immunotherapy

11:20-11:40 **Aron Popovtzer** MD
The role of immunotherapy in the practical clinic

11:40-12:00 **Gil Bar Sela** MD
The expected and the surprising side effects of Immunotherapy

3rd Session

12:00-12:30 Sponsored by 
Delivering innovative healthcare
Yehuda Zadik DMD
Prevention of medication related osteonecrosis of the jaw

12:30-12:50 **Silviu Brill** MD
Management of pain in cancer patients

12:50-13:00 Business meeting – ISOM members only

13:00-14:00 Lunch break

4th Session

- 14:00-14:20 **Abraham Hirshberg MD, DMD**
Nanophotonics as a tool for early cancer detection
- 14:20-14:40 **Ludmila Lukach DMD and Irit Allon DMD, PhD**
Oral lymphoma: Roadmap towards diagnosis, examples from Barzilai University Medical Center (BUMC)
- 14:40-15:00 **Tali Shani DMD, PhD**
Multidisciplinary team meetings for cancer patients: A literature review and the role of the oral medicine specialist

15:00-15:30 **Coffee break and poster exhibition**

5th Session

- 15:30-15:50 **Dalit Porat Ben Amy DMD, MSc**
Pre-treatment dental evaluation
- 15:50-16:10 **Noam Yarom DMD**
Management of cancer patients with medication related osteonecrosis of the jaw (MRONJ)
- 16:10-16:30 Oral presentations
- 16:30-16:40 Best posters awards

Friday, November 2nd

08:00-09:00 Registration

6th Session

- 09:00-09:20 **Navot Givol, DMD**
Trismus as a late complication of head and neck radiotherapy
- 09:20-09:50 **Cherry L Estilo DMD**
Development of a nomogram to predict radiation dosimetric distribution in different regions of the jaw in patients receiving head and neck intensity-modulated radiation therapy
- 09:50-10:10 **Cyril Meyerowitz DDS, MS**
The National Dental Practice-Based Research Network – an opportunity for oral cancer research

7th Session

- 10:10-10:40 **Stephen T Sonis** DMD, DMSc
Current advances in the prevention and treatment of oral mucositis
- 10:40-11:00 **Rakefet Czerninski** DMD
Dysplasia – now what?

11:00-11:30 Coffee break and poster exhibition

8th Session

- 11:30-11:40 Honorary member award to **Prof. Amos Buchner**
- 11:40-12:00 **Amos Buchner** DMD, MSD
History of oral pathology in Israel
- 12:00-12:20 **Marilena Vered** DMD
An update on prognostic factors for oral cancer patients with emphasis on the changes of the 2017 American Joint Committee on Cancer (AJCC) staging manual
- 12:20-12:40 **Doron Aframian** DMD, MSc, PhD
Salivary glands dysfunction in cancer patients
- 12:40-13:20 Brunch and poster exhibition

9th Session - Case presentations – post-graduate programs

- 13:20-13:30 **Rafael Cohen** DMD, Ariela Arad MD, Naama Keshet DMD
Ado-trastuzumab emtansine-associated gingival and subdural hemorrhage in metastatic breast cancer
- 13:30-13:40 **Aya Pessing Shabi** DMD, **Marilena Vered** DMD, **Ayelet Zlotogorski-Hurvitz** DMD
The equivocal diagnosis of oral lichenoid lesions appearing after rituximab administration
- 13:40-13:50 **Jacob Pettesh** DMD, **Irit Allon** DMD PhD, **Anna Pikovsky** DMD
Denosumab induced osteomyelitis mimicking periodontal disease
- 13:50-14:00 **Manal Watfa** BDS, **Zinat Awadieh** DMD, **Tali Shani** DMD PhD, **Granot Yigal** DMD
Oral surgery prior to bisphosphonates treatment initiation – are 21 days enough?

SPONSORS



OFAKIM Travel and Congresses Ltd.

Tel: 972-3-7610897, Email: avivm@ofakim.co.il